<DOC>
	<DOCNO>NCT00523640</DOCNO>
	<brief_summary>The purpose study find effect ( good bad ) combination chemotherapy drug gemcitabine , capecitabine , bevacizumab patient kidney cancer .</brief_summary>
	<brief_title>A Phase II Trial Gemcitabine , Capecitabine , Bevacizumab Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description>- determine objective response rate estimate time progression combination gemcitabine , capecitabine , bevacizumab patient metastatic clear cell renal cell cancer ; - determine survival combination gemcitabine , capecitabine , bevacizumab patient metastatic cell renal cell cancer ; - determine toxicity combination gemcitabine , capecitabine , bevacizumab patient metastatic renal cell cancer ; - collect baseline serum plasma sample exploration possible prognostic predictive marker</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Histologically cytologically confirm metastatic clear cell renal cell cancer Measurable disease Age 18 old ECOG performance status 0 1 Blood pressure less 140/90 2 separate occasion 6 week prior enrollment less 24 hour apart Normal organ function Women childbearing potential men must agree use adequate contraception Ability understand willingness sign write informed consent document follow require study procedure Patients chemotherapy radiotherapy within 4 week prior enter study recover adverse event due agent administer 4 week earlier Patients may prior treatment pyrimidine analog VEGF bind agent Patients may receive investigational therapeutic agent Patients may receive therapeutic anticoagulation warfarin , congener , heparin , low molecular weight heparinoids , specific thrombin inhibitor , similar agent Patients receive low dose coumadin ( 1 mg daily ) central line patency eligible Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior treatment start , anticipation need major surgical procedure course study Fine needle aspiration core biopsy within 7 day prior treatment start acceptable Serious , nonhealing wound , ulcer , bone fracture Evidence bleed diathesis coagulopathy Patients know brain metastasis Uncontrolled intercurrent illness Pregnant woman HIVpositive patient receive combination antiretroviral therapy exclude study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>metastatic</keyword>
	<keyword>renal cell</keyword>
	<keyword>kidney</keyword>
	<keyword>neoplasm</keyword>
</DOC>